New 4,5-Diarylimidazol-2-ylidene-iodidogold(I) Complexes with High Activity against Esophageal Adenocarcinoma Cells

Int J Mol Sci. 2023 Mar 17;24(6):5738. doi: 10.3390/ijms24065738.

Abstract

Inspired by the vascular-disrupting agent combretastatin A-4 and recently published anticancer active N-heterocyclic carbene (NHC) complexes of Au(I), a series of new iodidogold(I)-NHC complexes was synthesized and characterized. The iodidogold(I) complexes were synthesized by a route involving van Leusen imidazole formation and N-alkylation, followed by complexation with Ag2O, transmetalation with chloro(dimethylsulfide)gold(I) [Au(DMS)Cl], and anion exchange with KI. The target complexes were characterized by IR spectroscopy, 1H and 13C NMR spectroscopy, and mass spectrometry. The structure of 6c was validated via single-crystal X-ray diffraction. A preliminary anticancer screening of the complexes using two esophageal adenocarcinoma cell lines showed promising nanomolar activities for certain iodidogold(I) complexes accompanied with apoptosis induction, as well as c-Myc and cyclin D1 suppression in esophageal adenocarcinoma cells treated with the most promising derivative 6b.

Keywords: anticancer agents; carbene ligands; esophageal cancer; gold; metal-based drugs.

MeSH terms

  • Adenocarcinoma* / drug therapy
  • Cell Death
  • Coordination Complexes* / chemistry
  • Coordination Complexes* / pharmacology
  • Crystallography, X-Ray
  • Gold / chemistry
  • Heterocyclic Compounds* / chemistry
  • Humans
  • Methane / chemistry
  • Molecular Structure

Substances

  • Gold
  • Methane
  • Coordination Complexes
  • Heterocyclic Compounds